^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | gemcitabine (DNA synthesis inhibitor) + Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
53P - Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: A preliminary analysis of safety and efficacy of an open-label phase II clinical study
Published date:
09/14/2020
Excerpt:
Treatment-naive pts with aBTC received toripalimab (240mg, iv, Q3W), combined with GS (gemcitabine...Pts with TP53 or ATM alterations had a shorter PFS than wild-type pts (6 months vs. 10.5 months, p=0.036, and 2.8 months vs. 8.2 months, p=0.00037, respectively).
Trial ID:
